Skip to content
RELIS Logo RELIS Logo
  • Hjem
  • Bivirkninger
  • Om RELIS
    • Om RELIS
    • RELIS Midt-Norge
    • RELIS Nord-Norge
    • RELIS Sør-Øst
    • RELIS Vest
  • Hjem
  • Bivirkninger
  • Om RELIS
    • Om RELIS
    • RELIS Midt-Norge
    • RELIS Nord-Norge
    • RELIS Sør-Øst
    • RELIS Vest
  • Hjem
  • Bivirkninger
  • Om RELIS
  • RELIS Midt-Norge
  • RELIS Nord-Norge
  • RELIS Sør-Øst
  • RELIS Vest

NB! Denne utredningen er mer enn 5 år gammel.

Polypharmacy among patients admitted to hospital with rheumatic diseases

  • Publisert: 01.08.2001

Aim

This study describes polypharmacy among patients admitted to hospital with rheumatic diseases.

Methods
The study was performed in departments of rheumatology at nine Norwegian hospitals during five weeks in 1998. Pharmacists recorded all drugs on admittance among patients 18 years or older with rheumatic diseases.

Results
Sixty percent of 313 patients had polypharmacy defined as the concurrent use of five or more drugs, and this was most frequent among the older patients. However, they used fewer antirheumatic drugs compared to the younger patients. With regard to the three most common drug groups, older patients used more corticosteroids, and less nonsteroidal antiinflammatory drugs (NSAIDs)and disease modifying antirheumatic drugs (DMARDs), compared to the younger. Eighty-four percent of patients on methotrexate used folic acid, but only 52% of the patients who used corticosteroids used calcium supplements.

Conclusion
Polypharmacy among patients with rheumatic diseases is common, and the present description could be useful for drug-related interventions.

Skrevet av

Viktil KK, Enstad M, Kutschera J, Smedstad LM, Schjøtt J.

Publisert i

Pharmacy World & Science

Utredningen er utarbeidet på grunnlag av tilgjengelig litteratur og ressurser på publiseringstidspunktet. Innholdet i utredningen oppdateres ikke etter publisering. Helsepersonell er selv ansvarlig for bruk av utredningens innhold i rådgivning eller pasientbehandling.

  • 2001, Administrasjon og dosering, Artikler, Behandling, Bivirkninger

Del denne artikkelen:

Facebook
Twitter
LinkedIn

Nyttige lenker

Meld mistenkte bivirkninger

Still spørsmål

Kurs & seminarer

KUPP

Tryggmammamedisin

Sidekart

  • Hjem
  • Bivirkninger
  • Om RELIS
    • Om RELIS
    • RELIS Midt-Norge
    • RELIS Nord-Norge
    • RELIS Sør-Øst
    • RELIS Vest

Kontakt oss

Tekniske henvendelser sendes til:
IKT-skjema

Nyhetsbrev

Copyright © 2026 RELIS
FacebookTwitter
Page load link